TYK MEDICINES-B (02410) surged more than 13% during the morning session. As of the time of writing, the stock was up 8.94%, trading at HK$13.52, with a turnover of HK$40.70 million.

The company announced that its self-developed Class 1 new drug, Aimdotinib Mesylate Tablets (TY-9591 tablets), has been included in the Priority Review品种名单 by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).

This drug is intended for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have EGFR exon 19 deletion or exon 21 substitution mutations and are accompanied by central nervous system metastases.

Inclusion in the Priority Review signifies a comprehensive acceleration of the evaluation process for Aimdotinib Mesylate Tablets, potentially leading to an earlier market launch and providing a new treatment option for patients in China.